Clinical Trial Update: Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)

View source ↗

Summary

Completion of a regulatory post-marketing surveillance study for the Hepatitis A vaccine AVAXIM 160U by Sanofi Pasteur.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• AVAXIM 160U (Hepatitis A vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis A | Status: COMPLETED